Suppression of T cells by myeloid-derived suppressor cells in cancer

Human Immunology

Volumn 78, Issue 2, 2017, Pages 113-119

  Chen, Jieying ^a   Ye, Yingnan ^a   Liu, Pengpeng ^a   Yu, Wenwen ^a   Wei, Feng ^a   Li, Hui ^a   Yu, Jinpu ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Immune suppression; Myeloid derived suppressor cell; T cell; Targeted therapy

Indexed keywords

ARGININE; CHEMOKINE; CYSTINE; ECALECTIN; INTERLEUKIN 10; INTERLEUKIN 6; METALLOPROTEINASE; PHENYLALANINE; PROGRAMMED DEATH 1 LIGAND 1; TRANSFORMING GROWTH FACTOR BETA; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

APOPTOSIS; CANCER IMMUNOLOGY; CELL SUBPOPULATION; HUMAN; MALIGNANT NEOPLASM; MYELOID-DERIVED SUPPRESSOR CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; IMMUNITY; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; TUMOR ESCAPE;

ANIMALS; HUMANS; IMMUNITY; IMMUNOSUPPRESSION; IMMUNOTHERAPY; MYELOID-DERIVED SUPPRESSOR CELLS; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 85007575465     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2016.12.001     Document Type: Review

References (91)

1. [1] Young, M.R., Newby, M., Wepsic, H.T., Hematopoiesis and suppressor bone marrow cells in mice bearing large metastatic Lewis lung carcinoma tumors. Cancer Res. 47:1 (1987), 100–105.
2. [2] Pak, A.S., Wright, M.A., Matthews, J.P., Collins, S.L., Petruzzelli, G.J., Young, M.R., Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin. Cancer Res. 1:1 (1995), 95–103.
3. [3] Greten, T.F., Manns, M.P., Korangy, F., Myeloid derived suppressor cells in human diseases. Int. Immunopharmacol. 11:7 (2011), 802–807.
4. [4] Solito, S., Marigo, I., Pinton, L., Damuzzo, V., Mandruzzato, S., Bronte, V., Myeloid-derived suppressor cell heterogeneity in human cancers. Ann. N. Y. Acad. Sci. 1319 (2014), 47–65.
5. [5] Zhao, F., Obermann, S., von Wasielewski, R., Haile, L., Manns, M.P., Korangy, F., et al. Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma. Immunology 128:1 (2009), 141–149.
6. [6] Gallina, G., Dolcetti, L., Serafini, P., De Santo, C., Marigo, I., Colombo, M.P., et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J. Clin. Invest. 116:10 (2006), 2777–2790.
7. [7] Ochoa, A.C., Zea, A.H., Hernandez, C., Rodriguez, P.C., Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res. 13:2 Pt 2 (2007), 721s–726s.
8. [8] Almand, B., Clark, J.I., Nikitina, E., van Beynen, J., English, N.R., Knight, S.C., et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166:1 (2001), 678–689.
9. [9] Schmielau, J., Finn, O.J., Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 61:12 (2001), 4756–4760.
10. [10] Diaz-Montero, C.M., Salem, M.L., Nishimura, M.I., Garrett-Mayer, E., Cole, D.J., Montero, A.J., Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58:1 (2009), 49–59.
11. [11] Peranzoni, E., Zilio, S., Marigo, I., Dolcetti, L., Zanovello, P., Mandruzzato, S., et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22:2 (2010), 238–244.
12. [12] Chen, M.F., Kuan, F.C., Yen, T.C., Lu, M.S., Lin, P.Y., Chung, Y.H., et al. IL-6-stimulated CD11b+ CD14+ HLA-DR- myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus. Oncotarget 5:18 (2014), 8716–8728.
13. [13] Murdoch, C., Muthana, M., Coffelt, S.B., Lewis, C.E., The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8:8 (2008), 618–631.
14. [14] Sinha, P., Clements, V.K., Bunt, S.K., Albelda, S.M., Ostrand-Rosenberg, S., Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179:2 (2007), 977–983.
15. [15] Srivastava, M.K., Zhu, L., Harris-White, M., Kar, U.K., Huang, M., Johnson, M.F., et al. Myeloid suppressor cell depletion augments antitumor activity in lung cancer. PLoS ONE, 7(7), 2012, e40677.
16. [16] Soliman, H., Immunotherapy strategies in the treatment of breast cancer. Cancer Control. 20:1 (2013), 17–21.
17. [17] Khaled, Y.S., Ammori, B.J., Elkord, E., Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol. Cell Biol. 91:8 (2013), 493–502.
18. [18] Yao, X., Huang, J., Zhong, H., Shen, N., Faggioni, R., Fung, M., et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol. Ther. 141:2 (2014), 125–139.
19. [19] Guo, Y., Xu, F., Lu, T., Duan, Z., Zhang, Z., Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat. Rev. 38:7 (2012), 904–910.
20. [20] Coussens, L.M., Werb, Z., Inflammation and cancer. Nature 420:6917 (2002), 860–867.
21. [21] Coward, J., Kulbe, H., Chakravarty, P., Leader, D., Vassileva, V., Leinster, D.A., et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin. Cancer Res. 17:18 (2011), 6083–6096.
22. [22] Egler, R.A., Burlingame, S.M., Nuchtern, J.G., Russell, H.V., Interleukin-6 and soluble interleukin-6 receptor levels as markers of disease extent and prognosis in neuroblastoma. Clin. Cancer Res. 14:21 (2008), 7028–7034.
23. [23] Ohki, S., Shibata, M., Gonda, K., Machida, T., Shimura, T., Nakamura, I., et al. Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer. Oncol. Rep. 28:2 (2012), 453–458.
24. [24] Mundy-Bosse, B.L., Young, G.S., Bauer, T., Binkley, E., Bloomston, M., Bill, M.A., et al. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4(+) T cells from patients with GI malignancy. Cancer Immunol. Immunother. 60:9 (2011), 1269–1279.
25. [25] Tsukamoto, H., Nishikata, R., Senju, S., Nishimura, Y., Myeloid-derived suppressor cells attenuate TH1 development through IL-6 production to promote tumor progression. Cancer Immunol. Res. 1:1 (2013), 64–76.
26. [26] Rodriguez, P.C., Ochoa, A.C., Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol. Rev. 222 (2008), 180–191.
27. [27] Kusmartsev, S., Nefedova, Y., Yoder, D., Gabrilovich, D.I., Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172:2 (2004), 989–999.
28. [28] Suzuki, S., Shibata, M., Gonda, K., Kanke, Y., Ashizawa, M., Ujiie, D., et al. Immunosuppression involving increased myeloid-derived suppressor cell levels, systemic inflammation and hypoalbuminemia are present in patients with anaplastic thyroid cancer. Mol. Clin. Oncol. 1:6 (2013), 959–964.
29. [29] Hart, K.M., Byrne, K.T., Molloy, M.J., Usherwood, E.M., Berwin, B., IL-10 immunomodulation of myeloid cells regulates a murine model of ovarian cancer. Front Immunol., 2, 2011, 29.
30. [30] Sahakian, E., Powers, J.J., Chen, J., Deng, S.L., Cheng, F., Distler, A., et al. Histone deacetylase 11: a novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Mol. Immunol. 63:2 (2015), 579–585.
31. [31] Villagra, A., Cheng, F., Wang, H.W., Suarez, I., Glozak, M., Maurin, M., et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat. Immunol. 10:1 (2009), 92–100.
32. [32] Letterio, J.J., Roberts, A.B., Regulation of immune responses by TGF-beta. Annu. Rev. Immunol. 16 (1998), 137–161.
33. [33] Chikamatsu, K., Sakakura, K., Toyoda, M., Takahashi, K., Yamamoto, T., Masuyama, K., Immunosuppressive activity of CD14+ HLA-DR- cells in squamous cell carcinoma of the head and neck. Cancer Sci. 103:6 (2012), 976–983.
34. [34] Chen, W., Jin, W., Hardegen, N., Lei, K.J., Li, L., Marinos, N., et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198:12 (2003), 1875–1886.
35. [35] Ghiringhelli, F., Puig, P.E., Roux, S., Parcellier, A., Schmitt, E., Solary, E., et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 202:7 (2005), 919–929.
36. [36] Schlecker, E., Stojanovic, A., Eisen, C., Quack, C., Falk, C.S., Umansky, V., et al. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J. Immunol. 189:12 (2012), 5602–5611.
37. [37] Bronte, V., Zanovello, P., Regulation of immune responses by L-arginine metabolism. Nat. Rev. Immunol. 5:8 (2005), 641–654.
38. [38] Zea, A.H., Rodriguez, P.C., Atkins, M.B., Hernandez, C., Signoretti, S., Zabaleta, J., et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65:8 (2005), 3044–3048.
39. [39] Rodriguez, P.C., Zea, A.H., Culotta, K.S., Zabaleta, J., Ochoa, J.B., Ochoa, A.C., Regulation of T cell receptor CD3zeta chain expression by L-arginine. J. Biol. Chem. 277:24 (2002), 21123–21129.
40. [40] Rodriguez, P.C., Quiceno, D.G., Ochoa, A.C., L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109:4 (2007), 1568–1573.
41. [41] Rodriguez, P.C., Ernstoff, M.S., Hernandez, C., Atkins, M., Zabaleta, J., Sierra, R., et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 69:4 (2009), 1553–1560.
42. [42] Soliman, H., Mediavilla-Varela, M., Antonia, S., Indoleamine 2,3-dioxygenase: is it an immune suppressor?. Cancer J. 16:4 (2010), 354–359.
43. [43] Kallberg, E., Wikstrom, P., Bergh, A., Ivars, F., Leanderson, T., Indoleamine 2,3-dioxygenase (IDO) activity influence tumor growth in the TRAMP prostate cancer model. Prostate 70:13 (2010), 1461–1470.
44. [44] Yu, J., Du, W., Yan, F., Wang, Y., Li, H., Cao, S., et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J. Immunol. 190:7 (2013), 3783–3797.
45. [45] Yu, J., Wang, Y., Yan, F., Zhang, P., Li, H., Zhao, H., et al. Noncanonical NF-kappaB activation mediates STAT3-stimulated IDO upregulation in myeloid-derived suppressor cells in breast cancer. J. Immunol. 193:5 (2014), 2574–2586.
46. [46] Boulland, M.L., Marquet, J., Molinier-Frenkel, V., Moller, P., Guiter, C., Lasoudris, F., et al. Human IL4I1 is a secreted L-phenylalanine oxidase expressed by mature dendritic cells that inhibits T-lymphocyte proliferation. Blood 110:1 (2007), 220–227.
47. [47] Carbonnelle-Puscian, A., Copie-Bergman, C., Baia, M., Martin-Garcia, N., Allory, Y., Haioun, C., et al. The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages. Leukemia 23:5 (2009), 952–960.
48. [48] Srivastava, M.K., Sinha, P., Clements, V.K., Rodriguez, P., Ostrand-Rosenberg, S., Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 70:1 (2010), 68–77.
49. [49] Eagle, H., Washington, C., Friedman, S.M., The synthesis of homocystine, cystathionine, and cystine by cultured diploid and heteroploid human cells. Proc. Natl. Acad. Sci. U.S.A. 56:1 (1966), 156–163.
50. [50] Ishii, I., Akahoshi, N., Yu, X.N., Kobayashi, Y., Namekata, K., Komaki, G., et al. Murine cystathionine gamma-lyase: complete cDNA and genomic sequences, promoter activity, tissue distribution and developmental expression. Biochem. J. 381:Pt 1 (2004), 113–123.
51. − cystine transporter: a new action for an old drug. Leukemia 15:10 (2001), 1633–1640.
52. [52] Gmunder, H., Eck, H.P., Droge, W., Low membrane transport activity for cystine in resting and mitogenically stimulated human lymphocyte preparations and human T cell clones. Eur. J. Biochem. 201:1 (1991), 113–117.
53. [53] Bannai, S., Transport of cystine and cysteine in mammalian cells. Biochim. Biophys. Acta 779:3 (1984), 289–306.
54. [54] Arner, E.S., Holmgren, A., Physiological functions of thioredoxin and thioredoxin reductase. Eur. J. Biochem. 267:20 (2000), 6102–6109.
55. [55] Mansoor, M.A., Svardal, A.M., Ueland, P.M., Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma. Anal. Biochem. 200:2 (1992), 218–229.
56. [56] Gmunder, H., Eck, H.P., Benninghoff, B., Roth, S., Droge, W., Macrophages regulate intracellular glutathione levels of lymphocytes. Evidence for an immunoregulatory role of cysteine. Cell. Immunol. 129:1 (1990), 32–46.
57. [57] Iwata, S., Hori, T., Sato, N., Ueda-Taniguchi, Y., Yamabe, T., Nakamura, H., et al. Thiol-mediated redox regulation of lymphocyte proliferation. Possible involvement of adult T cell leukemia-derived factor and glutathione in transferrin receptor expression. J. Immunol. 152:12 (1994), 5633–5642.
58. [58] Sato, H., Watanabe, H., Ishii, T., Bannai, S., Neutral amino acid transport in mouse peritoneal macrophages. J. Biol. Chem. 262:27 (1987), 13015–13019.
59. [59] Otsuji, M., Kimura, Y., Aoe, T., Okamoto, Y., Saito, T., Oxidative stress by tumor-derived macrophages suppresses the expression of CD3 zeta chain of T-cell receptor complex and antigen-specific T-cell responses. Proc. Natl. Acad. Sci. U.S.A. 93:23 (1996), 13119–13124.
60. [60] Corzo, C.A., Cotter, M.J., Cheng, P., Cheng, F., Kusmartsev, S., Sotomayor, E., et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J. Immunol. 182:9 (2009), 5693–5701.
61. [61] Huang, A., Zhang, B., Wang, B., Zhang, F., Fan, K.X., Guo, Y.J., Increased CD14(+)HLA-DR (−/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol. Immunother. 62:9 (2013), 1439–1451.
62. [62] Bingisser, R.M., Tilbrook, P.A., Holt, P.G., Kees, U.R., Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J. Immunol. 160:12 (1998), 5729–5734.
63. [63] Harari, O., Liao, J.K., Inhibition of MHC II gene transcription by nitric oxide and antioxidants. Curr. Pharm. Des. 10:8 (2004), 893–898.
64. [64] Rivoltini, L., Carrabba, M., Huber, V., Castelli, C., Novellino, L., Dalerba, P., et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol. Rev. 188 (2002), 97–113.
65. [65] Gabrilovich, D.I., Nagaraj, S., Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9:3 (2009), 162–174.
66. [66] Gabrilovich, D.I., Ostrand-Rosenberg, S., Bronte, V., Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12:4 (2012), 253–268.
67. [67] Nagaraj, S., Gupta, K., Pisarev, V., Kinarsky, L., Sherman, S., Kang, L., et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat. Med. 13:7 (2007), 828–835.
68. [68] Lu, T., Ramakrishnan, R., Altiok, S., Youn, J.I., Cheng, P., Celis, E., et al. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J. Clin. Invest. 121:10 (2011), 4015–4029.
69. [69] Molon, B., Ugel, S., Del Pozzo, F., Soldani, C., Zilio, S., Avella, D., et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J. Exp. Med. 208:10 (2011), 1949–1962.
70. [70] Raber, P.L., Thevenot, P., Sierra, R., Wyczechowska, D., Halle, D., Ramirez, M.E., et al. Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways. Int. J. Cancer 134:12 (2014), 2853–2864.
71. [71] Dolcetti, L., Peranzoni, E., Ugel, S., Marigo, I., Fernandez Gomez, A., Mesa, C., et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 40:1 (2010), 22–35.
72. [72] Movahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111:8 (2008), 4233–4244.
73. [73] Youn, J.I., Nagaraj, S., Collazo, M., Gabrilovich, D.I., Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181:8 (2008), 5791–5802.
74. [74] Watanabe, S., Deguchi, K., Zheng, R., Tamai, H., Wang, L.X., Cohen, P.A., et al. Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes. J. Immunol. 181:5 (2008), 3291–3300.
75. [75] Rosen, S.D., Ligands for L-selectin: homing, inflammation, and beyond. Annu. Rev. Immunol. 22 (2004), 129–156.
76. [76] Hanson, E.M., Clements, V.K., Sinha, P., Ilkovitch, D., Ostrand-Rosenberg, S., Myeloid-derived suppressor cells down-regulate L-selectin expression on CD4+ and CD8+ T cells. J. Immunol. 183:2 (2009), 937–944.
77. [77] Monney, L., Sabatos, C.A., Gaglia, J.L., Ryu, A., Waldner, H., Chernova, T., et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415:6871 (2002), 536–541.
78. [78] Zhu, C., Anderson, A.C., Schubart, A., Xiong, H., Imitola, J., Khoury, S.J., et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6:12 (2005), 1245–1252.
79. [79] Dardalhon, V., Anderson, A.C., Karman, J., Apetoh, L., Chandwaskar, R., Lee, D.H., et al. Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells. J. Immunol. 185:3 (2010), 1383–1392.
80. [80] Norde, W.J., Maas, F., Hobo, W., Korman, A., Quigley, M., Kester, M.G., et al. PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation. Cancer Res. 71:15 (2011), 5111–5122.
81. [81] Duraiswamy, J., Freeman, G.J., Coukos, G., Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res. 73:23 (2013), 6900–6912.
82. [82] Yin, Y., Huang, X., Lynn, K.D., Thorpe, P.E., Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation. Cancer Immunol. Res. 1:4 (2013), 256–268.
83. [83] Shen, L., Sundstedt, A., Ciesielski, M., Miles, K.M., Celander, M., Adelaiye, R., et al. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunol. Res. 3:2 (2015), 136–148.
84. [84] Forghani, P., Waller, E.K., Poly (I: C) modulates the immunosuppressive activity of myeloid-derived suppressor cells in a murine model of breast cancer. Breast Cancer Res. Treat. 153:1 (2015), 21–30.
85. [85] Long, A.H., Highfill, S.L., Cui, Y., Smith, J.P., Walker, A.J., Ramakrishna, S., et al. Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol. Res. 4:10 (2016), 869–880.
86. [86] Soong, R.S., Anchoori, R.K., Yang, B., Yang, A., Tseng, S.H., He, L., et al. RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells. Oncotarget, 2016.
87. [87] Trikha, P., Plews, R.L., Stiff, A., Gautam, S., Hsu, V., Abood, D., et al. Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator. Oncoimmunology, 5(9), 2016, e1214787.
88. [88] Holmgaard, R.B., Zamarin, D., Lesokhin, A., Merghoub, T., Wolchok, J.D., Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine 6 (2016), 50–58.
89. [89] Ye, C., Geng, Z., Dominguez, D., Chen, S., Fan, J., Qin, L., et al. Targeting ornithine decarboxylase by alpha-difluoromethylornithine inhibits tumor growth by impairing myeloid-derived suppressor cells. J. Immunol. 196:2 (2016), 915–923.
90. [90] Blidner, A.G., Salatino, M., Mascanfroni, I.D., Diament, M.J., de Kier, Bal., Joffe, E., Jasnis, M.A., et al. Differential response of myeloid-derived suppressor cells to the nonsteroidal anti-inflammatory agent indomethacin in tumor-associated and tumor-free microenvironments. J. Immunol. 194:7 (2015), 3452–3462.
91. [91] Hossain, F., Al-Khami, A.A., Wyczechowska, D., Hernandez, C., Zheng, L., Reiss, K., et al. Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies. Cancer Immunol. Res. 3:11 (2015), 1236–1247.